Listen to article
6:17Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 15 September 2026
Read article
Published on 15 September 2026
Read article
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Let's be honest, the world has gone a bit mad for weight-loss drugs. You can't open a newspaper or scroll through social media without hearing about the latest 'miracle jab'. For the pharmaceutical giants behind them, it has been nothing short of a gold rush, with billions pouring in as waistlines shrink. But whenever a market gets this hot, you can be sure of one thing, a politician will eventually show up to throw a spanner in the works. And right on cue, former President Trump has pledged to take aim at their sky-high prices.
To me, this is where things get properly interesting for investors. When the golden goose gets a fright, the whole farmyard is thrown into disarray.
The current market leaders have had a spectacular run. They created a product that everyone, it seems, wants. The profits have been astronomical, and their share prices have reflected that. But the prospect of government-enforced price negotiations changes the entire equation. Suddenly, those beautiful, wide profit margins look a lot less certain.
I’ve seen this play out before. Political pressure on a lucrative industry creates a ripple effect. The big, established players, once seen as invincible, suddenly have to look over their shoulders. Their business model, built on premium pricing, could face a fundamental threat. This isn't just idle chatter, it's a potential earthquake for the sector, and the first tremors are already being felt in the market. The question is, who stands to benefit from the aftershocks?
This is where the opportunity lies, in my view. When the market leaders are forced onto the defensive, it creates an opening for the smaller, more innovative upstarts. A whole host of biotech firms have been beavering away in their labs, developing the next generation of obesity treatments. They might have different mechanisms, better side-effect profiles, or, crucially, more convenient delivery methods. Think a simple pill instead of a weekly injection.
This is a classic case of disruption, a theme we've explored in our Weight-Loss Drug Shakeup: What's Next for Biotechs? basket, where political winds could fill the sails of smaller, more nimble companies. Firms like ORAMED PHARMACEUTICALS, working on oral delivery, or BIOMEA FUSION, with its novel approaches, could suddenly find themselves in a very favourable position. If the current blockbusters become less profitable or accessible due to price controls, doctors and patients will naturally start looking for alternatives.
Of course, you shouldn't invest based on a politician's promise alone. The real story here is the underlying innovation. The current crop of drugs are impressive, but they are not the final word on obesity treatment. The biotech sector is brimming with companies trying to build a better mousetrap. They are exploring everything from treatments for rare genetic disorders of obesity, like Rhythm Pharmaceuticals, to therapies that offer a completely different way of tackling metabolic health.
The political pressure simply acts as a potential catalyst. It could accelerate the shift towards these newer, potentially superior, alternatives. Healthcare systems are groaning under the cost of obesity, and if a cheaper, effective option comes along whilst the market leader is tangled in pricing battles, its path to adoption could be much quicker. This combination of genuine scientific progress and a shifting market landscape is what makes this a compelling, if speculative, thesis. Investing here is a bet that the future of weight-loss treatment will be more diverse than it is today.
View the full Basket:Weight-Loss Drug Shakeup: What's Next for Biotechs?
View the full Basket:Weight-Loss Drug Shakeup: What's Next for Biotechs?
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 15 September 2026
Read article
Published on 15 September 2026
Read article
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
